141 related articles for article (PubMed ID: 7496837)
1. Axillary node status in nonpalpable breast cancer.
Dowlatshahi K; Snider HC; Kim R
Ann Surg Oncol; 1995 Sep; 2(5):424-8. PubMed ID: 7496837
[TBL] [Abstract][Full Text] [Related]
2. Nonpalpable breast cancer: needle-localized biopsy for diagnosis and considerations for treatment.
Marrujo G; Jolly PC; Hall MH
Am J Surg; 1986 May; 151(5):599-602. PubMed ID: 3010754
[TBL] [Abstract][Full Text] [Related]
3. Mammographically detected breast cancer. Nonpalpable is not a synonym for inconsequential.
Schwartz GF; Carter DL; Conant EF; Gannon FH; Finkel GC; Feig SA
Cancer; 1994 Mar; 73(6):1660-5. PubMed ID: 8156493
[TBL] [Abstract][Full Text] [Related]
4. Clinically occult breast carcinoma: diagnostic approaches and role of axillary node dissection.
Meterissian S; Fornage BD; Singletary SE
Ann Surg Oncol; 1995 Jul; 2(4):314-8. PubMed ID: 7552620
[TBL] [Abstract][Full Text] [Related]
5. Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
Danforth DN; Findlay PA; McDonald HD; Lippman ME; Reichert CM; d'Angelo T; Gorrell CR; Gerber NL; Lichter AS; Rosenberg SA
J Clin Oncol; 1986 May; 4(5):655-62. PubMed ID: 3701387
[TBL] [Abstract][Full Text] [Related]
6. Staging and treatment of clinically occult breast cancer.
Schwartz GF; Feig SA; Rosenberg AL; Patchefsky AS; Schwartz AB
Cancer; 1984 Mar; 53(6):1379-84. PubMed ID: 6692326
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
8. Treatment and survival of female patients with nonpalpable breast carcinoma.
Tinnemans JG; Wobbes T; Holland R; Hendriks JH; Van der Sluis RF; De Boer HH
Ann Surg; 1989 Feb; 209(2):249-53. PubMed ID: 2537064
[TBL] [Abstract][Full Text] [Related]
9. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.
Kumar R; Jana S; Heiba SI; Dakhel M; Axelrod D; Siegel B; Bernik S; Mills C; Wallack M; Abdel-Dayem HM
J Nucl Med; 2003 Jan; 44(1):7-10. PubMed ID: 12515869
[TBL] [Abstract][Full Text] [Related]
11. Significance and staging of nonpalpable carcinomas of the breast.
Schwartz GF; Feig SA; Patchefsky AS
Surg Gynecol Obstet; 1988 Jan; 166(1):6-10. PubMed ID: 2827328
[TBL] [Abstract][Full Text] [Related]
12. Pathologic findings in nonpalpable invasive breast cancer.
McKinney CD; Frierson HF; Fechner RE; Wilhelm MC; Edge SB
Am J Surg Pathol; 1992 Jan; 16(1):33-6. PubMed ID: 1309412
[TBL] [Abstract][Full Text] [Related]
13. Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes.
Plecha D; Bai S; Patterson H; Thompson C; Shenk R
Ann Surg Oncol; 2015 Dec; 22(13):4241-6. PubMed ID: 25814365
[TBL] [Abstract][Full Text] [Related]
14. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes.
Fein DA; Fowble BL; Hanlon AL; Hooks MA; Hoffman JP; Sigurdson ER; Jardines LA; Eisenberg BL
J Surg Oncol; 1997 May; 65(1):34-9. PubMed ID: 9179265
[TBL] [Abstract][Full Text] [Related]
15. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
16. Axillary node metastasis from T1N0M0 breast cancer: possible avoidance of dissection in a subgroup.
Iwasaki Y; Fukutomi T; Akashi-Tanaka S; Nanasawa T; Tsuda H
Jpn J Clin Oncol; 1998 Oct; 28(10):601-3. PubMed ID: 9839499
[TBL] [Abstract][Full Text] [Related]
17. [Axillary lymph node dissection in clinically occult breast cancer].
Le Bouëdec G; Pomel C; Chamussy E; Feillel V; de Latour M; Dauplat J
Bull Cancer; 1996 Jul; 83(7):581-8. PubMed ID: 8868947
[TBL] [Abstract][Full Text] [Related]
18. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
20. Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer.
Park SH; Kim MJ; Park BW; Moon HJ; Kwak JY; Kim EK
Ann Surg Oncol; 2011 Mar; 18(3):738-44. PubMed ID: 20890729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
